Aptevo Therapeutics Inc. — Director's Dealing 2017

Mar 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2017-03-01

Reporting Person: Stromatt Scott C (Chief Medical Officer and SVP)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-01	Common Stock	M	16269	—	Acquired	45894	Direct
2017-03-01	Common Stock	F	5312	$2.02	Disposed	40582	Direct
2017-03-09	Common Stock	M	13902	—	Acquired	54484	Direct
2017-03-09	Common Stock	F	3678	$1.80	Disposed	50806	Direct
2017-03-10	Common Stock	M	24836	—	Acquired	75642	Direct
2017-03-10	Common Stock	F	6570	$1.78	Disposed	69072	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-01	Restricted Stock Unit	$	M	16269	Disposed		Common Stock (16269)	Direct
2017-03-09	Restricted Stock Unit	$	M	13902	Disposed		Common Stock (13902)	Direct
2017-03-10	Restricted Stock Unit	$	M	24836	Disposed		Common Stock (24836)	Direct

Footnotes

F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.

F2: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date.

F3: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 13,902 on March 9, 2017 and 13,892 on March 9, 2018.

F4: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017.